Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development | News
Search Refinements

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
91-105 of 3791 results
HD Biosciences, Marshall University enter drug discovery co-development deal
By PBR Staff Writer
HD Biosciences, a China-based biology-focused preclinical drug discovery contract research organization (CRO), the Marshall Institute for Interdisciplinary Research (MIIR) and the Marshall University Joan C. Edwards School of Medicine have announced a new partnership to co-develop potential anti-cancer drugs for unmet healthcare needs in both international and Chinese markets.
Drug Research > Drug Discovery & Development > News
Threshold starts dosing in Phase I/II trial of myeloma combination drug TH-302/Bortezomib
By PBR Staff Writer
Threshold Pharmaceuticals has initiated dosing patients in the final stage of an ongoing Phase I/II trial of its investigational hypoxia-activated prodrug, TH-302, in combination with the proteasome inhibitor bortezomib (Velcade) and low-dose dexamethasone (TBorD) for the treatment of relapsed/refractory multiple myeloma.
Drug Research > Drug Discovery & Development > News
Compugen discloses achievement of milestone in cancer immunotherapy collaboration with Bayer
Compugen has disclosed that it has achieved the initial milestone in the cancer immunotherapy collaboration it entered last year with Bayer HealthCare (Bayer).
Drug Research > Drug Discovery & Development > News
BioMarin gets Health Canada approval of VIMIZIM to treat morquio a syndrome
BioMarin Pharmaceutical has announced that Health Canada has approved VIMIZIM(elosulfase alfa) for long-term enzyme replacement therapy in patients with a confirmed diagnosis of mucopolysaccharidosis IVA (MPS IVA), also known as Morquio A syndrome.
Drug Research > Drug Discovery & Development > News
Yabao Pharma, Eli Lilly to jointly develop diabetes treatment
By PBR Staff Writer
China-based Yabao Pharmaceutical has entered into a strategic partnership with Eli Lilly and Company to jointly develop Lilly's glucokinase activator (GKA), LY2608204, which has completed Phase I studies in the US in addition to extensive pre-clinical development.
Drug Research > Drug Discovery & Development > News
Bayer's Nexavar gets Health Canada approval for differentiated thyroid cancer
Bayer is pleased to announce the Health Canada approval of Nexavar for the treatment of patients with locally advanced or metastatic, progressive, differentiated thyroid carcinoma (DTC), refractory to radioactive iodine (RAI).
Drug Research > Drug Discovery & Development > News
Celladon announces new clinical development initiatives for MYDICAR
Celladon Corporation has launched two new clinical development initiatives for MYDICAR(R), its lead product candidate, in patients with end-stage renal disease (ESRD) undergoing surgery for arteriovenous fistula (AVF) creation in preparation for hemodialysis, and in advanced heart failure patients with systolic dysfunction that were previously excluded from MYDICAR trials due to pre-existing levels of neutralizing antibodies.
Drug Research > Drug Discovery & Development > News
Debiopharm, Nobelex to develop new antibiotics for N. Gonorrhoeae and Enteric Species
By PBR Staff Writer
Swiss biopharmaceutical firm Debiopharm and Canada-based CAnaNobelex Biotech have entered into collaboration for two discovery programs for the development of new antibiotics targeting Neisseria gonorrhoeae and enteric species using a new mechanism of action.
Drug Research > Drug Discovery & Development > News
Morphotek, Sorrento to develop morphotek antibody drug conjugates
By PBR Staff Writer
Concortis Biosystems, a subsidiary of Sorrento Therapeutics, has announced a collaboration to develop new antibody drug conjugates (ADCs) based on a Morphotek antibody linked to chemotherapeutic agents using Concortis' proprietary ADC Technology.
Drug Research > Drug Discovery & Development > News
Orexo reports top-line data from Phase III trial of Zubsolv to treat opioid dependence
Orexo has announced top-line data from a Phase 3 clinical trial demonstrating that Zubsolv (buprenorphine/naloxone CIII sublingual tablet) is as effective as Suboxone film in the treatment of opioid dependence.
Drug Research > Drug Discovery & Development > News
Mersana, EMD Serono to develop new antibody-drug conjugates
By PBR Staff Writer
US-based Mersana Therapeutics has entered into an agreement with Merck's biopharmaceutical division EMD Serono, to jointly develop next-generation antibody-drug conjugates (ADCs).
Drug Research > Drug Discovery & Development > News
TG Therapeutics, Ligand ink licensing deal to develop inhibitors of IRAK4
By PBR Staff Writer
US-based clinical-stage biopharmaceutical firm TG Therapeutics has entered into an agreement with Ligand Pharmaceuticals (LGND) to license exclusive global rights to develop and commercialize Ligand's Interleukin-1 Receptor Associated Kinase 4 (IRAK4) inhibitor research program.
Drug Research > Drug Discovery & Development > News
BIND, Roche partner to discovery new nanomedicines
By PBR Staff Writer
BIND Therapeutics, a US-based clinical-stage nanomedicine platform company, has entered into a research agreement with Roche to discover new nanomedicines using Accurins to treat diseases in therapeutic areas outside of oncology.
Drug Research > Drug Discovery & Development > News
Merrimack Pharmaceuticals to regain worldwide rights to develop and commercialize MM-121
Merrimack Pharmaceuticals has reached an agreement with Sanofi to regain worldwide rights to develop and commercialize MM-121, a monoclonal antibody designed to block ErbB3 (HER3) activation in patients with heregulin-positive tumors and improve response to standard of care treatments.
Drug Research > Drug Discovery & Development > News
Navitor Pharmaceuticals announces $23.5m Series A financing
Navitor Pharmaceuticals, a biopharmaceutical company developing novel medicines by targeting cellular nutrient signaling, has announced a $23.5m Series A financing.
Drug Research > Drug Discovery & Development > News
91-105 of 3791 results